SS
EFTR

Steve Schonfeld’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Steve Schonfeld’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,131
Closed -$1.24M – 2406
2021
Q1 		$1.24M Buy
+5,131
New +$1.26M 0.02% 813

Other funds holding EFTR

ECP
Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Steve Schonfeld's EFTR Position: Q2 2021 in Review

Steve Schonfeld sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q2 2021, closing a stake of 5,131 shares — an estimated $1.24M sold.

Steve Schonfeld first reported a position in EFTR in Q1 2021 and held it in 1 quarter. The position peaked at $1.24M in Q1 2021. 58 funds tracked by Wall St. Rank hold EFTR as of Q2 2021.

  • Steve Schonfeld reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Steve Schonfeld sold 5,131 eFFECTOR Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $1.24M.
  • Steve Schonfeld first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Steve Schonfeld's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $1.24M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.